Journal Title：Current Opinion In Immunology

Current Opinion in Immunology aims to stimulate scientifically grounded, interdisciplinary, multi-scale debate and exchange of ideas. It contains polished, concise and timely reviews and opinions, with particular emphasis on those articles published in the past two years. In addition to describing recent trends, the authors are encouraged to give their subjective opinion of the topics discussed.

In Current Opinion in Immunology we help the reader by providing in a systematic manner: 1. The views of experts on current advances in their field in a clear and readable form. 2. Evaluations of the most interesting papers, annotated by experts, from the great wealth of original publications.

Current Opinion in Immunology will serve as an invaluable source of information for researchers, lecturers, teachers, professionals, policy makers and students.

Current Opinion in Immunology builds on Elsevier's reputation for excellence in scientific publishing and long-standing commitment to communicating reproducible biomedical research targeted at improving human health. It is a companion to the new Gold Open Access journal Current Research in Immunology and is part of the Current Opinion and Research(CO+RE) suite of journals. All CO+RE journals leverage the Current Opinion legacy-of editorial excellence, high-impact, and global reach-to ensure they are a widely read resource that is integral to scientists' workflow.

《免疫學最新觀點》旨在促進基于科學、跨學科、多尺度的辯論和思想交流。它包含精煉、簡潔和及時的評論和觀點，特別強調(diào)過去兩年發(fā)表的文章。除了描述最新趨勢外，還鼓勵作者對所討論的主題發(fā)表主觀意見。

在《免疫學最新觀點》中，我們通過系統(tǒng)的方式幫助讀者：1. 專家對其領(lǐng)域當前進展的看法，形式清晰易讀。2. 對大量原始出版物中最有趣的論文進行評估，并由專家注釋。

《免疫學最新觀點》將成為研究人員、講師、教師、專業(yè)人士、政策制定者和學生的寶貴信息來源。

《免疫學最新觀點》以愛思唯爾在科學出版方面的卓越聲譽和長期致力于傳播旨在改善人類健康的可重復生物醫(yī)學研究為基礎(chǔ)。它是新黃金開放獲取期刊《免疫學研究》的姊妹刊，也是《當前觀點與研究》（CO+RE）期刊系列的一部分。所有 CO+RE 期刊都利用《當前觀點》的傳統(tǒng)——編輯卓越、影響力大、全球影響力——確保它們成為廣泛閱讀的資源，是科學家工作流程不可或缺的一部分。

Current Opinion In Immunology創(chuàng)刊于1988年，由Elsevier Ltd出版商出版，收稿方向涵蓋醫(yī)學 - 免疫學全領(lǐng)域，此刊是該細分領(lǐng)域中屬于非常不錯的SCI期刊，在行業(yè)細分領(lǐng)域中學術(shù)影響力較大，專業(yè)度認可很高，所以對原創(chuàng)文章要求創(chuàng)新性較高，如果您的文章質(zhì)量很高，可以嘗試。平均審稿速度 較慢,6-12周 ，影響因子指數(shù)6.6，該期刊近期沒有被列入國際期刊預警名單，廣大學者值得一試。